Fog Begins to Lift with Q3 Biotech Numbers Certain market indicators for 2003�s third quarter suggest that at least some […]

India emerges as new drug trial hot spot Biotech entrepreneurs see Indian clinical trials � which can cut costs by

Who’s Going To Pay For Global Health? The amazingly swift global response to the SARS outbreak earlier this year demonstrated

Who’s Going To Pay For Global Health? The amazingly swift global response to the SARS outbreak earlier this year demonstrated

Seeking a Prescription for Biogenerics No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now

Why Merck Missed the Mark S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report

Biotech: Teva’s Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market

Biotech: Teva’s Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market

Gene Therapy Rebuilds Gums Gene therapy can restore damage caused by severe gum disease, suggest animal studies.

Is Viagra Vulnerable? Eli Lilly’s Cialis lasts for 36 hours–and a $100 million ad blitz will spread the word